The FTSE 100 benefitted from a mining rally as the sector dismissed the latest round of tariffs from China on US goods.

Antofagasta topped the blue-chip risers with a 5.9% rise to 837p, Peers Anglo American added 5% to £16.55 and Evraz strengthened 3.6% to 527.4p.

The FTSE 100 closed 0.4% higher at 7,331.

Wall Street was also enjoying a strong performance with the exception of the tech-heavy Nasdaq index, down 0.1% at 7,946 around 4:45pm UK time.

Brent crude oil was up 0.4% at $79.32 per barrel.

MID AND LARGE CAP RISERS AND FALLERS

Weaker sales at B&Q and a disappointing performance in France hit profitability at Kingfisher as underlying pre-tax profits fell 14.8% to £375m in the six months to 31 July. The stock declined 6.3% to 247p.

UK supermarket Tesco launched its new discount store chain Jack's to take on rivals Aldi and Lidl, but this failed to excite the market as the shares advanced only 0.3% to 235.8p.

Elsewhere in the sector, the Competition and Markets Authority referred Sainsbury's £7.3bn takeover of Asda for an in-depth review. Shares in Sainsbury's retreated 1.2% to 316.8p.

Engineering design software specialist Aveva was flat at £28.42 despite robust trading and confirmation it is targeting operating profit margins of 30% via operating efficiencies and cutting costs.

Babcock reported trading was in line with expectations with an order book of £18bn and a pipeline worth £14bn, causing the stock to accelerate 3.4% to 715.6p.

SMALL CAP RISERS AND FALLERS

Shares in Premaitha Health received a 14.2% boost to 14.4p on a legal settlement and a licence and supply partnership deal with Illumina, resolving the infringement litigation.

Futura Medical revealed it plans to take erectile dysfunction treatment MED2002 through Phase II development before partnering or selling the asset to generate higher prices. Shares in the pharma firm plummeted 41.5% to 15p as Futura explores options for additional funding.

Gulf Marine Services rallied 9.1% to 45.3p after winning three long-term contracts in the Middle East and North Africa (MENA) region.

ReNeuron dropped 17.3% to 67p on the news that an unnamed US-based specialty pharma company decided it will no longer progress to a definitive licensing deal.